tbuckley/cabot-search huggingface dataset:
DDIS-17. SMALL MOLECULE INHIBITORS OF C1qBP FOR THERAPEUTIC INTERVENTION IN GLIOMA
Authors: Natsuko Nomura, Elmar Nurmemmedov, Satheesh Ravula, Valentina Kouznetsova, Igor Tsigelny, Venkata Yenugonda, Santosh Kesari, Ivan Babic
Journal: Neuro-Oncology (2016)

The immune complement cascade, initiated by the protein C1q, has an important role in brain development. C1q has complement independent functions in the brain such as microglial activation and neuroprotection. However, within the aging brain, C1q protein levels can dramatically increase (almost 300-fold) resulting in neurodegenerative disease. Recently, it was reported that C1q secreted within the tumor microenvironment acts as a cancer-promoting factor through a complement independent mechanism, likely mediated by binding to its receptor C1qBP (aka gC1qR, p32, HABP1). We have demonstrated that C1qBP (p32) is upregulated in patient derived glioma stem-like cells (GSC’s), and our studies were the first to demonstrate that knockdown of C1qBP in patient derived GSC’s inhibits tumor growth in vitro and in vivo. Thus, inhibiting C1qBP function, has potential for therapeutic intervention. C1qBP is a multifunctional multicompartment molecule localized to mitochondria, cytosol, nucleus, and cell surface. It was shown by several groups that tumor cell proliferation could be inhibited by either an anti-C1qBP monoclonal antibody recognizing the C1q binding site, or by a tumor homing peptide (LyP-1) binding to the C1qBP site. However, the limited permeability of peptides and mAb’s to cross the blood brain barrier (BBB) makes small molecule inhibitors a better approach to inhibit C1qBP in the CNS. We have employed pharmacophore modeling of C1q and LyP-1 binding to C1qBP and have compiled a list of compounds that could bind to C1qBP. We performed an initial screen of 40 compounds for direct binding to C1qBP, and tested for inhibition of C1qBP function in multiple cell-based assays. This approach has yielded a compound that binds to C1qBP and shows moderate inhibitory activity toward C1qBP. Our high throughput strategy and cell-based assays are designed to identify a small molecule inhibitor of C1qBP amenable for structure-activity relationship (SAR) for preclinical development.
Prognostic assessment in Abiraterone Acetate (AA) post-Docetxel (DOC) mCRPC cohort
Authors: C. Cavaliere, O. Caffo, C. Ortega, C. D'Aniello, S.C. Cecere, M. Di Napoli, C. Della Pepa, A. Crispo, F. Maines, F. Ruatta, G. Iovane, M. Montella, S. Pisconti, S. Pignata, G. Facchini
Journal: Annals of Oncology (2016)
QLIF-11. CLASSIFICATION OF DERMATOLOGIC ADVERSE EVENTS AND MANAGEMENT STRATEGIES IN PATIENTS RECEIVING THERAPY WITH OPTUNE FOR HIGH GRADE GLIOMAS
Authors: David Jennings, Ashley Sumrall
Journal: Neuro-Oncology (2016)

OptuneTM is an FDA-approved novel delivery system which administers tumor treatment fields in the management of newly diagnosed and recurrent glioblastoma (GBM). Recommended usage is 18 hours per day, which may be limited by its only significant adverse event: medical site reaction or skin reaction. An attempt to describe these dermatologic adverse events (dAEs) was proposed by Lacouture et al in mid-2014. Unfortunately, this system was not readily adopted into clinical practice and was not included as part of the sentinel EF-14 trial. Skin reactions (dAEs) were reported as 16% for the EF-11 patients and 43% for the patients participating in EF-14. Additionally, the classification of dAEs are not adequately described via the CTCAE, which is the standard for describing adverse events. We have proposed an algorithm for the identification and management of dAEs which incorporates four categories: contact dermatitis (allergic and irritant), erosions, ulcerations, and folliculitis. Each category is unique in its management and impact on delivery of therapy. We implemented this algorithm in the management of patients treated with OptuneTM via clinical trial and/or prescription between April 2014 and present. In a population of 33 patients with high grade gliomas (HGGs), we identified dAEs in approximately 30% of patients treated with OptuneTM for a minimum of seven days. Of those patients, contact dermatitis was the most common dAE, representing 24% (n=8). This only led to treatment interruption in one individual. Folliculitis affected only 6% (n=2) and was easily managed via topical therapy. Erosions were seen in 18% (n=6) and were managed with topical therapy, rearrangement of arrays, trimming adhesive dressings, and did not necessitate therapy interruption. Ulcerations were observed in 6% (n=2), requiring therapy cessation while administering systemic antibiotics. By accurately identifying and managing these dAEs, patients are more likely to remain on OptuneTM therapy and derive clinical benefit.
Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma
Authors: Andreas Engert, Carsten Kobe, Heinz Haverkamp, Georg Kuhnert, Jana Markova, Andreas Lohri, Susanne Klutmann, Holger Amthauer, Volker Diehl, Peter Borchmann, Markus Dietlein
Journal: Blood (2012)
F18 NaF PET/CT and whole body MRI for the detection of metastases in patients with biochemical recurrence of prostate cancer
Authors: P. Twardowski, S.K. Pal, C. Stein, P. Frankel, H. Chen, T. Moore, D. Harwood, M. Prajapati, M. Junqueira, S. Chung, S. Rahmanuddin, K. Burns, O. Rodriguez, D. Woo, P. Tryon, J. Park
Journal: Annals of Oncology (2016)
Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
Authors: T. Kaneda, H. Yoshioka, M. Tamiya, A. Tamiya, A. Hata, A. Okada, T. Niwa, T. Shiroyama, M. Kanazu, T. Ishida, N. Katakami
Journal: Annals of Oncology (2016)
Concerns of young women with breast cancer and theirs partners from chemotherapy to follow-up: a cross-sectional study
Authors: L. Vanlemmens, A. Congard, C. Duprez, A.-S. Baudry, A. Lesur, C. Loustalot, C. Guillemet, M. Leclercq, C. Levy, D. Carlier, C. Lefeuvre-Plesse, H. Simon, J.-S. Frenel, P. Antoine, V. Christophe
Journal: Annals of Oncology (2016)
Prognostic Impact of Elevated Pretransplant Serum Ferritin in Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Anuj Mahindra, Brian Bolwell, Ronald Sobecks, Lisa Rybicki, Stacey Brown, Brad Pohlman, Robert Dean, Steve Andresen, Matt Kalaycio, John Sweetenham, Edward Copelan
Journal: Blood (2007)
Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B.
Authors: Rafael Fonseca, Scott Van Wier, Wee-Joo Chng, Rhett Ketterling, Martha Lacy, Angela Dispenzieri, Peter Leif Bergsagel, S. Vincent Rajkumar, Philip Greipp, Mark Litzow, Shaji Kumar, Natalia Gonzalez-Paz, Kim Henderson, Gregory Ahmann, Morie Gertz
Journal: Blood (2005)
Anti-tumor activity of recombinant human CXCR2-Fc protein
Authors: K.A. Glukhova, Y.A. Trizna, A.S. Glukhov, V.V. Marchenkov, G.V. Afanasieva, A.A. Ivanov, O.P. Popova, T.I. Danilova, I.P. Beletsky, O.V. Prusakova
Journal: Annals of Oncology (2016)
Clinical characteristics of colorectal cancer patients with brain metastases: An "Association des Gastro-Éntérologues Oncologues" (AGEO) multicenter study
Authors: P. Roussille, M. Dior, C. Locher, M. Mabro, P. Artru, G. Tachon, É Frouin, A. Berger, M. Wager, J.-M. Goujon, L. Karayan-Tapon, D. Tougeron
Journal: Annals of Oncology (2016)
GENT-29. CLINICAL EXPERIENCE OF GLIOMA SURGERY USING “TAILED BULLET”: OVERCOMING THE LIMITATIONS OF CONVENTIONAL NEURO-NAVIGATION GUIDED SURGERY
Authors: Jin Mo Cho, Kyunggi Cho, Se Hyuk Kim
Journal: Neuro-Oncology (2016)

Although conventional neuro-navigation is a useful tool for image-guided glioma surgery, there are several limitations, such as brain shift. We introduce our methods using an identifiable marker, a “tailed bullet”, to overcome the limitation of conventional neuro-navigation. A tailed bullet is an identifiable marker that determines the extent of a resection and we introduce our technique and reviewed the clinical results. Tailed bullet resections were carried out for 110 glioma cases (WHO grade 2, 3 and 4 glioma was 14, 36 and 60 cases, respectively). We achieved a gross total resection (GTR) in 71 patients (64.5%), subtotal resection (STR) in 36 patients (32.7%), and partial resection (PR) in 3 patients (2.7%). The overall median survival (OS) duration of grade 3 and 4 gliomas were 20.9 (range, 1.2 ~ 82.4) and 13.6 months (range, 1.4 ~ 173.4), respectively. Extent of resection (GTR), younger age, and higher initial Karnofsky Performance Score (KPS) were related to longer overall survival (OS) for grade-4 gliomas. There was no significant adverse event directly related to the use of tailed bullets. Considering the limitations of conventional neuro-navigation methods, the tailed bullets could be helpful during glioma resection. We believe the method to be easy to apply technique and overcomes the limitation from the conventional neuro-navigation. Further studies are needed to verify the clinical benefits of using tailed bullets.
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma
Authors: M. Johannsen, A. Roemer, G. Spitaleri, G. Curigliano, L. Giovannoni, H. D. Menssen, L. Zardi, D. Neri, K. Miller, F. G. de Braud
Journal: Journal of Clinical Oncology (2008)

16032 Background: L19-IL2 is a tumor targeted immunocytokine constituted by a single chain Fragment variable (scFv) format directed against the ED-B domain of fibronectin and the human cytokine interleukin-2 (IL2). We carried out a phase I/II study in patients with solid tumors to assess safety, pharmacokinetics (PK), and early signs of activity of L19-IL2 monotherapy. Methods: L19-IL2 was administered as an i.v. infusion at doses of 5 (n=1), 10 (n=1), 22.5 (n=15) and 30 MioIU IL2 equivalent dose (n=1) on days 1, 3 and 5 every 21 days. Serum samples for PK assessment were collected on day 1, 3, 5 and 10 of each cycle. Flow cytometry (marker panels: T-cells CD71/CD8/CD3/CD4; NK/B-cells CD71/CD19/CD3/CD56; IL-2R-positive T-cells CD25/-CD122/CD3/CD4) and assessment of human antifusion protein antibodies to L19 (HAFA) were performed at screening and on day 1, 3, 5 and 10 of each cycle. Data on safety and activity were evaluated using CTC v3.0 and RECIST criteria, respectively. Results: Among the total 33 patients,18 had progressive advanced renal clear-cell carcinoma (RCC). Of these, 6 were treated in the phase I and a further 12 planned patients with RCC in the phase II part of the study. The 30 MiU IL2 equivalent dose was considered toxic. The 22.5 MiU dose was determined to be the MTD, which was selected to be the RD. Total/median number of cycles was 62/4 (2–6). Median age was 62 years (52–74). 15 of 18 patients had received prior systemic therapy. We recorded three grade 3 toxicities: 1 hypertension and hypoxia, 1 dyspnoea, and 1 renal failure. All other toxicities were moderate and transient. There were no treatment-related deaths. 16 patients are evaluable for response. We observed stable disease in 13 patients (81%) and progressive disease in 3 (19%) after six infusions of L19-IL2. Immunophenotyping analysis showed stimulation of NK cells being by far the strongest, followed by T4 cells and CTLs. Pharmacokinetic analysis and HAFA development data will be shown. Conclusions: The part II of this study confirms that L19-IL2 can be safely administered repeatedly in patients with advanced RCC at 22.5 Mio IU IL2 equivalent dose. Preliminary evaluation suggests clinical activity in these mostly pretreated patients. Toxicity was manageable and reversible. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer, Philogen, Philogen SPA Philogen SPA Bayer, Schering AG Philogen SPA
Roche asks WHO to remove Avastin from essential medicines list
Authors: Deborah Cohen
Journal: BMJ (2017)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Roche asks WHO to remove Avastin from essential medicines list Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Hepatic Steatosis Does Not Result in Insulin Resistance in Subjects With Familial Hypobetalipoproteinaemia
Authors: M.E. Visser, N.M. Lammers, A. Heerschap, M. van der Graaf, M.T. Ackermans, H.P. Sauerwein, M.J. Serlie, E.S. Stroes
Journal: Circulation (2009)
A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.
Authors: Steven J. Lemery, Matthew M. Hsieh, Aleah Smith, Sheila Rao, Hanh M. Khuu, Donohue Theresa, Jennifer M. Karpovich, Lisa Cook, Rose Goodwin, Carol Boss, Gary Calandra, Nancy Geller, John Tisdale, Richard Childs
Journal: Blood (2007)
Impact of fluid status and inflammation and their interaction on survival: a study in an international hemodialysis patient cohort
Authors: Marijke J.E. Dekker, Daniele Marcelli, Bernard J. Canaud, Paola Carioni, Yuedong Wang, Aileen Grassmann, Constantijn J.A.M. Konings, Peter Kotanko, Karel M. Leunissen, Nathan W. Levin, Frank M. van der Sande, Xiaoling Ye, Vaibhav Maheshwari, Len A. Usvyat, Jeroen P. Kooman
Journal: Kidney International (2017)

In hemodialysis patients extracellular fluid overload is a predictor of all-cause and cardiovascular mortality, and a relation with inflammation has been reported in previous studies. The magnitude and nature of this interaction and the effects of moderate fluid overload and extracellular fluid depletion on survival are still unclear. We present the results of an international cohort study in 8883 hemodialysis patients from the European MONDO initiative database where, during a three-month baseline period, fluid status was assessed using bioimpedance and inflammation by C-reactive protein. All-cause mortality was recorded during 12 months of follow up. In a second analysis a three-month baseline period was added to the first baseline period, and changes in fluid and inflammation status were related to all-cause mortality during six-month follow up. Both pre-dialysis estimated fluid overload and fluid depletion were associated with an increased mortality, already apparent at moderate levels of estimated pre-dialysis fluid overload (1.1-2.5L); hazard ratio 1.64 (95% confidence interval 1.35-1.98). In contrast, post-dialysis estimated fluid depletion was associated with a survival benefit (0.74 [0.62-0.90]). The concurrent presence of fluid overload and inflammation was associated with the highest risk of death. Thus, while pre-dialysis fluid overload was associated with inflammation, even in the absence of inflammation, fluid overload remained a significant risk factor for short-term mortality, even following improvement of fluid status.
ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study
Authors: Jatin J Shah, Jeffrey Zonder, Adam Cohen, Robert Z. Orlowski, Raymond Alexanian, Sheeba K Thomas, Donna Weber, Jonathan L. Kaufman, R. Donald Harvey, Duncan Walker, Kevin Litwiler, Sharon Karan, Brandi Hilder, Ann Marie Ptaszynski, Sagar Lonial
Journal: Blood (2011)
Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC)
Authors: N. Reguart, L. Paré, A. Giménez-Capitán, C. Teixidó, P. Galván, S. Viteri, S. Rodríguez, V. Peg, E. Aldeguer, E. Ovalle, N. Viñolas, S. Merkelbach-Bruse, F. Lopez-Rios, R. Rosell, M.Á Molina-Vila, A. Prat
Journal: Annals of Oncology (2016)
Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&amp;N Unicancer Group PACSA trial with the REFCOR
Authors: J. Guigay, F. Bidault, J. Fayette, C. Even, D. Cupissol, F. Rolland, F. Peyrade, B. Laguerre, C. Le Tourneau, S. Zanetta, L. Bozec Le Moal, C. Borel, L. Digue, J. Delaye, S. Diffetocq, V. Costes, A. Auperin, L. Faivre
Journal: Annals of Oncology (2016)
Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)
Authors: G. Marín Zafra, Jbar Te Masso, J.M. Rodriguez Gonzalez, P. Segura Luque, J.L. Alonso Romero, T. García, P. Sanchez Henarejos, A. Soto, M.J. Martinez
Journal: Annals of Oncology (2016)
EXTH-52. ASSESSMENT OF TRYPTOPHAN UPTAKE AND KINETICS USING 1-(2-[F-18]FLUOROETHYL)-TRYPTOPHAN AND α-[C-11]-METHYL-L-TRYPTOPHAN PET IMAGING IN MICE IMPLANTED WITH PATIENT-DERIVED BRAIN TUMOR XENOGRAFTS
Authors: Sharon K Michelhaugh, Otto Muzik, Anthony R. Guastella, Neil V Klinger, Lisa A. Polin, Hancheng Cai, Yangchun Xin, Thomas J. Mangner, Csaba Juhasz, Sandeep Mittal
Journal: Neuro-Oncology (2016)

Abnormal tryptophan metabolism via the kynurenine pathway (KP) is involved in the pathophysiology of a wide variety of human diseases including cancers. α-[11C]-methyl-L-tryptophan (AMT) positron emission tomography (PET) imaging demonstrated increased tryptophan uptake and trapping in epileptic foci and various brain tumors, but the short half-life of 11C limits its widespread clinical application. Recent in vitro studies suggested that the novel radiotracer 1-(2-[18F]fluoroethyl)-tryptophan ([18F]FETrp) may be useful to assess tryptophan metabolism via the KP. In this study, we tested in vivo organ and tumor uptake and kinetics of ([18F]FETrp in patient-derived xenograft mouse models and compared it with AMT uptake. Xenograft mouse models of glioblastoma and metastatic brain tumors (originating from lung and breast cancer) were developed by subcutaneous implantation of patient tumor fragments. Dynamic PET scans with [18F]FETrp and AMT were performed on mice bearing human brain tumors 1-7 days apart. The biodistribution and tumoral standardized uptake values (SUVs) for both tracers were determined and compared. [18F]FETrp showed prominent uptake in the pancreas and no bone uptake, whereas AMT showed higher uptake in kidneys. Both tracers showed uptake in the xenograft tumors with a plateau at about 30-min post-injection; however, [18F]FETrp showed higher tumoral SUV than AMT in all three tumor types tested. The radiation dosimetry for [18F]FETrp determined from the mouse scan data compared favorably to the clinically used 2-deoxy-2-[18F]fluoro-D-glucose (FDG) PET tracer. [18F]FETrp tumoral uptake, biodistribution and radiation dosimetry data provide strong preclinical evidence that this new radiotracer is worth further studies that may lead to a new, broadly-applicable molecular imaging tool to study abnormal tryptophan metabolism in human tumors.
The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse
Authors: Leo Rasche, Amy Buros, Niels Weinhold, Caleb K. Stein, James E McDonald, Shweta S. Chavan, Edgardo Angtuaco, Sharmilan Thanendrarajan, Carolina Schinke, Shmuel Yaccoby, Joshua Epstein, Frits van Rhee, Maurizio Zangari, Bart Barlogie, Brian A Walker, Faith E Davies, Gareth J Morgan
Journal: Blood (2016)
ACTR-40. CONVECTION-ENHANCED DELIVERY OF NIMUSTINE HYDROCHLORIDE (ACNU) AGAINST PATIENTS WITH RECURRENT MALIGNANT GLIOMAS: ON-GOING CLINICAL TRIAL
Authors: Ryuta Saito, Masayuki Kanamori, Yukihiko Sonoda, Jia Wenting, Takuhiro Shoji, Masashi Chonan, Shunji Mugikura, Takaki Murata, Toshihiro Kumabe, Teiji Tominaga
Journal: Neuro-Oncology (2016)

CONCLUSION: Higher histologic grade was associated with poor prognosis.Although radiation therapy was effective in most reported literatures, radiation alone was not effective.Chemotherapy suggested it was possible to be better prognosis.
Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma
Authors: Robert Chen, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Richard Klasa, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Anas Younes
Journal: Blood (2010)
BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
Authors: A. Goncalves, F. Viret, E. François, L. Dahan, H. Perrier, R. Lamy, D. Re, R. Largillier, M. Gasmi, X. Tchiknavorian, O. Turrini, L. Moureau-Zabotto, J. Delpero, P. Viens
Journal: Journal of Clinical Oncology (2011)

4028 Background: With its inhibitory effects against Raf-1 kinase and vascular endothelial growth factor receptor-2, sorafenib (S) is an oral anticancer agent targeting Ras-dependent signal transduction as well as angiogenic pathways. A phase I (Siu et al, 2006, Clin Cancer Res) demonstrated that gemcitabine (G) plus S combination was well tolerated and had activity in advanced pancreatic cancer (APC) patients (pts). The BAYPAN study was conducted to compare G+S versus G + placebo (P) in APC pts. Methods: This multicentric randomized phase III trial was double-blind, placebo-controlled. Eligible pts had locally advanced or metastatic pancreatic adenocarcinoma, no prior therapy for advanced disease and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. The primary end point was progression-free survival (PFS). The statistical hypothesis was an increase of median PFS from 3 to 6 months, with alpha and beta risks of 0.05 and 0.2 (power=80%), respectively, and required 104 pts to be enrolled. Pts were stratified by centre of inclusion, age (<70 or > 70 years) and extent of disease (locally advanced or metastatic). Pts received G 1,000 mg/m2 IV, weekly × 7 followed by 1 rest week, then weekly × 3 every 4 weeks + S 400 mg (GS) or P (GP), BID, continuously. Results: Between 12/2006 and 09/2009, 104 pts were enrolled (52 pts in each arm). Pt characteristics (GP/GS) were the following: median age (years): 64/61; sex (male, female): 30, 22/ 32, 20; metastatic, locally advanced (%): 79, 21/ 81, 19. Tolerance and response data will be available at the time of the meeting. Median follow-up was 27.7 mos.. As of 07/16/10, 98 pts (48/50) have progressed and 86 (43/43) have died. There was no significant difference in median PFS (GP= 5.6 mos. [3.4-7.6] versus GS= 3.8 mos. [3-6]; p=0.601, log-rank test). Median overall survivals were also similar (GP = 9.2 mos. [7.7-12.9] versus GS = 8.5 mos. [6-11.1]; p=0.146, log-rank test). Conclusions: The addition of S to G does not improve progression-free survival in APC pts.
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia.
Authors: Concetta Conticello, Luana Adamo, Luisa Vicari, Raffaella Giuffrida, Gioacchin Iannolo, Gabriele Anastasi, Giuseppe A. Palumbo, Massimo Gulisano, Ruggero De Maria, Rosario Giustolisi, Francesco Di Raimondo
Journal: Blood (2007)
Microenvironment-Mediated Bim Down-Regulation through Induction of Microrna-181a Protects Cells From Apoptosis In Mantle-Cell and Other Non-Hodgkin B-Cell Lymphomas
Authors: Tint Lwin, Jian-Hong Lin, Yong Sung Choi, Xinwei Zhang, Lynn Moscinski, Kenneth Wright, Eduardo M. Sotomayor, William Dalton, Jianguo Tao
Journal: Blood (2010)